Immunitybio Inc (IBRX)

$2.14 +0.04 (1.90%)
Market Cap 2.24B
Revenue (ttm) 14.75M
Net Income (ttm) -413.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,803.80%
Debt to Equity Ratio 0.00
Volume 5,408,700
Avg Vol 11,421,098
Day's Range N/A - N/A
Shares Out 984.97M
Stochastic %K 20%
Beta 0.10
Analysts Strong Sell
Price Target $10.40

Company Profile

ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead b...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 696 5235
Address:
3530 John Hopkins Court, San Diego, United States
Stocktud
Stocktud Dec. 25 at 12:07 AM
$IBRX Latest update https://x.com/gretchmick/status/2003922794120364113?s=46
0 · Reply
Intime32
Intime32 Dec. 24 at 9:57 PM
$IBRX Merry Christmas FDA!
0 · Reply
NTyoda
NTyoda Dec. 24 at 9:46 PM
$IBRX Holy cow!
6 · Reply
1iquid
1iquid Dec. 24 at 9:14 PM
💎 Liquid® Live Actionable Trade Asset: $IBRX Contracts: $IBRX January 15, 2027 $2 Calls Scale in: $0.82- $1.00 Scale out: $3.19-$5.47 Profit Potential : 362% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
JanetBSmellin
JanetBSmellin Dec. 24 at 8:47 PM
$IBRX Got some epic surf this morning, and upward movement here. Merry Christmas and Happy Holidays to all.
0 · Reply
listenteme
listenteme Dec. 24 at 8:38 PM
$IBRX Merry Christmas to all. Put away your phones and shut your computers off and forget about all the hate in the world for a couple of days and enjoy the most precious things in your life. Never forget about the almighty God and be kind and show love to others. The biggest winners in life are the ones who extend a hand in times of need and show love and compassion. Always remember money does not follow you to the cemetery. God bless you all.
1 · Reply
megamaven
megamaven Dec. 24 at 8:29 PM
$IBRX options market is pricing stagnant movement. Cheap calls cheap puts. Not much there.
1 · Reply
Jhankster60
Jhankster60 Dec. 24 at 8:05 PM
$IBRX Wishing everyone a Blessed Christmas and a healthy 2026. Safe travels wherever your celebrations take you.
0 · Reply
FiduciaryBooty
FiduciaryBooty Dec. 24 at 6:57 PM
$IBRX merry xmas turkeys
0 · Reply
jacksparo
jacksparo Dec. 24 at 6:54 PM
$IBRX $AKBA $OCGN $LAES Positive close and the weekly chart looks strong!
0 · Reply
Latest News on IBRX
ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer

Dec 16, 2025, 9:00 AM EST - 8 days ago

ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer

ImmunityBio Moves Closer To EU Approval For Bladder Cancer Therapy

Dec 12, 2025, 12:00 PM EST - 12 days ago

ImmunityBio Moves Closer To EU Approval For Bladder Cancer Therapy

ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe

Dec 12, 2025, 6:10 AM EST - 12 days ago

ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe

A Second Anktiva Approval Could Be The Catalyst ImmunityBio Needs

Dec 3, 2025, 5:00 AM EST - 21 days ago

A Second Anktiva Approval Could Be The Catalyst ImmunityBio Needs

ImmunityBio: Checking The Boxes Of A True Commercial-Stage Biotech

Nov 19, 2025, 4:56 AM EST - 5 weeks ago

ImmunityBio: Checking The Boxes Of A True Commercial-Stage Biotech

New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations

Nov 13, 2025, 9:00 AM EST - 5 weeks ago

New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations

Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024

Nov 4, 2025, 10:12 PM EST - 7 weeks ago

Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024

Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks

Oct 22, 2025, 1:42 PM EDT - 2 months ago

Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks

AI APLD ENVX HIMS PLUG RKT RXRX

ImmunityBio: A Small Bet Is Warranted

Oct 3, 2025, 1:24 PM EDT - 2 months ago

ImmunityBio: A Small Bet Is Warranted

ImmunityBio: Still Too Early To Judge Anktiva, Although Clock Is Ticking

Sep 11, 2025, 12:26 PM EDT - 3 months ago

ImmunityBio: Still Too Early To Judge Anktiva, Although Clock Is Ticking

ImmunityBio's ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy

Sep 8, 2025, 8:30 AM EDT - 3 months ago

ImmunityBio's ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy

Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio's ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device

Aug 26, 2025, 8:30 AM EDT - 4 months ago

Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio's ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device

ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID

Aug 19, 2025, 8:30 AM EDT - 4 months ago

ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID

ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy

Aug 13, 2025, 8:30 AM EDT - 4 months ago

ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy

ImmunityBio Announces Houston's Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients

Aug 11, 2025, 8:30 AM EDT - 4 months ago

ImmunityBio Announces Houston's Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients

ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code

Aug 5, 2025, 7:00 AM EDT - 5 months ago

ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code

ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors

Jul 25, 2025, 6:03 AM EDT - 5 months ago

ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors

ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates

Jul 25, 2025, 6:00 AM EDT - 5 months ago

ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates

ImmunityBio: Still Flashing Signs Of Life After Another Anktiva Approval

Jul 21, 2025, 10:45 AM EDT - 5 months ago

ImmunityBio: Still Flashing Signs Of Life After Another Anktiva Approval

UK MHRA Approves ImmunityBio's ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Jul 7, 2025, 9:43 PM EDT - 6 months ago

UK MHRA Approves ImmunityBio's ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze

Jun 12, 2025, 9:09 AM EDT - 6 months ago

ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze

ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer

Jun 3, 2025, 8:45 AM EDT - 7 months ago

ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors

Jun 2, 2025, 9:00 AM EDT - 7 months ago

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors

ImmunityBio, Saudi Arabia's Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East

May 27, 2025, 8:00 AM EDT - 7 months ago

ImmunityBio, Saudi Arabia's Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East

ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code

May 12, 2025, 6:30 AM EDT - 8 months ago

ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code

ImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLA

May 5, 2025, 5:05 PM EDT - 8 months ago

ImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLA

ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug

May 5, 2025, 9:21 AM EDT - 8 months ago

ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug

ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency's Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025

May 5, 2025, 6:30 AM EDT - 8 months ago

ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency's Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025

ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish

Apr 29, 2025, 12:50 PM EDT - 8 months ago

ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish

Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up

Apr 28, 2025, 8:30 AM EDT - 8 months ago

Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up

ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting

Apr 21, 2025, 4:21 PM EDT - 8 months ago

ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia

Apr 15, 2025, 8:00 AM EDT - 9 months ago

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia

ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor

Apr 8, 2025, 7:30 AM EDT - 9 months ago

ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor

ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch

Apr 7, 2025, 5:00 AM EDT - 9 months ago

ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch

ImmunityBio: Taking Care Of Business

Apr 3, 2025, 5:54 PM EDT - 9 months ago

ImmunityBio: Taking Care Of Business

ImmunityBio to Host Investor Day

Mar 26, 2025, 6:00 AM EDT - 9 months ago

ImmunityBio to Host Investor Day

ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching

Mar 13, 2025, 9:00 AM EDT - 10 months ago

ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching

ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum

Mar 7, 2025, 1:47 AM EST - 10 months ago

ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum

ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024

Mar 3, 2025, 7:30 AM EST - 10 months ago

ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024

ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer

Feb 27, 2025, 7:10 PM EST - 10 months ago

ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer

FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage

Feb 19, 2025, 9:00 AM EST - 11 months ago

FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage

ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Feb 13, 2025, 3:05 PM EST - 11 months ago

ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer

Jan 29, 2025, 8:30 AM EST - 11 months ago

ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer

ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Jan 27, 2025, 9:00 AM EST - 11 months ago

ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval

Jan 17, 2025, 2:05 PM EST - 1 year ago

ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval

ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details

Jan 16, 2025, 2:25 PM EST - 1 year ago

ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details

ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency

Jan 15, 2025, 5:20 PM EST - 1 year ago

ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency

ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom

Jan 15, 2025, 5:20 PM EST - 1 year ago

ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom

ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective

Jan 6, 2025, 9:00 AM EST - 1 year ago

ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective

Stocktud
Stocktud Dec. 25 at 12:07 AM
$IBRX Latest update https://x.com/gretchmick/status/2003922794120364113?s=46
0 · Reply
Intime32
Intime32 Dec. 24 at 9:57 PM
$IBRX Merry Christmas FDA!
0 · Reply
NTyoda
NTyoda Dec. 24 at 9:46 PM
$IBRX Holy cow!
6 · Reply
1iquid
1iquid Dec. 24 at 9:14 PM
💎 Liquid® Live Actionable Trade Asset: $IBRX Contracts: $IBRX January 15, 2027 $2 Calls Scale in: $0.82- $1.00 Scale out: $3.19-$5.47 Profit Potential : 362% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
JanetBSmellin
JanetBSmellin Dec. 24 at 8:47 PM
$IBRX Got some epic surf this morning, and upward movement here. Merry Christmas and Happy Holidays to all.
0 · Reply
listenteme
listenteme Dec. 24 at 8:38 PM
$IBRX Merry Christmas to all. Put away your phones and shut your computers off and forget about all the hate in the world for a couple of days and enjoy the most precious things in your life. Never forget about the almighty God and be kind and show love to others. The biggest winners in life are the ones who extend a hand in times of need and show love and compassion. Always remember money does not follow you to the cemetery. God bless you all.
1 · Reply
megamaven
megamaven Dec. 24 at 8:29 PM
$IBRX options market is pricing stagnant movement. Cheap calls cheap puts. Not much there.
1 · Reply
Jhankster60
Jhankster60 Dec. 24 at 8:05 PM
$IBRX Wishing everyone a Blessed Christmas and a healthy 2026. Safe travels wherever your celebrations take you.
0 · Reply
FiduciaryBooty
FiduciaryBooty Dec. 24 at 6:57 PM
$IBRX merry xmas turkeys
0 · Reply
jacksparo
jacksparo Dec. 24 at 6:54 PM
$IBRX $AKBA $OCGN $LAES Positive close and the weekly chart looks strong!
0 · Reply
BixbyKnolls
BixbyKnolls Dec. 24 at 6:44 PM
$IBRX indeed.. buying AH. Merry Xmas all!
0 · Reply
TonyLA
TonyLA Dec. 24 at 6:33 PM
$IBRX There's Paddy boy's Christmas present to u baggies! 3 pennies! He's your Santa daddy!! 😂🤡
0 · Reply
KissMyAngus02
KissMyAngus02 Dec. 24 at 6:30 PM
$IBRX all my shares were borrowed. Now, just 20%.
0 · Reply
dannymac65
dannymac65 Dec. 24 at 6:11 PM
$IBRX
1 · Reply
LadyQRex
LadyQRex Dec. 24 at 5:42 PM
$IBRX - Have a Merry Christmas 🎄 and a Happy Hanukkah to all who celebrate. Best wishes for a safe and pleasant holiday season!
1 · Reply
STLMO
STLMO Dec. 24 at 5:20 PM
$IBRX Couldn’t resist bought more earlier today. Wishing everyone a wonderful Merry Christmas.
0 · Reply
Freebird25
Freebird25 Dec. 24 at 5:09 PM
$IBRX Merry Christmas to all! Unfortunately, the gift of Anktiva will be late to the patients around the world (who sure could use a boost to their immune system for better over-all survival from many indications). Also late for us believers /investors in Dr. Soon-Shiong and the IBRX team. Maybe the gifts will still come, just a little late & arrive Soon after the new year. GLTA.
0 · Reply
burchrealtync
burchrealtync Dec. 24 at 5:05 PM
$IBRX Merry Christmas to you and yours. Thanks for your insights.
0 · Reply
Eureka2005
Eureka2005 Dec. 24 at 4:49 PM
$IBRX Our goal for the New Year is not to give up until ANKTIVA, the successful treatment against Glioblastoma, Lymphopenia, pancreatic, prostate, lung, colon, Non Hodgkin Lymphoma and Lynch syndrome (the cancer prevention vaccine), HIV is available to anyone who needs it. Hopefully President Trump in the State of the Nation address will include Dr. PSS’s Moonshot. We will stay firm until the thugs who are trying to destroy all the extraordinary achievements and efforts of Dr. PSS are obliterated in a short squeeze and losing malicious billions of dollars.
1 · Reply
OmarKingW
OmarKingW Dec. 24 at 4:03 PM
$IBRX When this explodes 💥 it will hurt them bad!!!!!keeping the lid on….
0 · Reply
BixbyKnolls
BixbyKnolls Dec. 24 at 4:02 PM
$IBRX rinse and repeat😜🚀💯
1 · Reply
Pacificview
Pacificview Dec. 24 at 4:02 PM
$IBRX Posted earlier today by PSS
1 · Reply